



Section 1 – Registrant’s Business and Operations

Item 1.01 Entry into a Material Definitive Agreement.

On January 21, 2019, Miragen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an eighth amendment (the “Amendment”) to that certain License and Collaboration Agreement (the “Servier Agreement”) between the Company and Les Laboratoires Servier and Institut de Recherches Servier, effective January 7, 2019.

The Amendment updates Section 3.8 of the Servier Agreement related to committee record keeping.

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment. The Company anticipates filing a copy of the Amendment with its annual report on Form 10-K for the fiscal year ended December 31, 2018.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Miragen Therapeutics, Inc.

Date: January 24, 2019

By: /s/ Jason A. Leverone  
Jason A. Leverone  
Chief Financial Officer